Aktualisierte Fassung

 

^* Diese Leitlinien wurden im Auftrag der Deutschen Gesellschaft für Phlebologie (DGP) ausgearbeitet und vom Vorstand und dem Wissenschaftlichen Beirat der DGP am 16. Juni 1996 verabschiedet (Erstpublikation: Phlebologie 1996; 25: 199-203). Diese Leitlinien berücksichtigen den aktuellen Stand der Literatur, jedoch nicht die in jedem Land unterschiedlichen Zulassungsbestimmungen für verschiedene Pharmaka. Zuletzt aktualisiert am 28.2.1998.

• Literatur

• 1 Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331: 1630-41.
• 2 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
• 3 Comerota AJ, Aldridge SC. Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg 1993; 36: 359-64.
• 4 Brandjes DPM, Büller HR, ten Cate JW. et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-62.
• 5 Wheeler HB, Hirsh J, Wells P, Anderson FA. Diagnostic tests for deep vein thrombosis. Arch Intern Med 1994; 154: 1921-8.
• 6 Wells PS, Hirsh J, Anderson DR, Lensing AWA. et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995; 345: 1326-30.
• 7 Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemostat 1994; 71: 1-6.
• 8 Wells PS, Brill-Edwards P, Stevens P. et al. A novel and rapid whole blood assay for Ddimer in patients with clinically suspected deep vein thrombosis. Circulation 1995; 91: 2184-7.
• 9 John MA, Elms MJ, O’Reilly EJ. et al. The simpliRED D-dimer test: a novel assay for the detection of cross-linked fibrin degradation products in whole blood. Thromb Res 1990; 58: 273-81.
• 10 Meyerovitz MF, Polak JF, Goldhaber SZ. Short-term response to thrombolytic therapy in deep venous thrombosis: predictive value of venographic appearance. Radiology 1992; 184: 345-8.
• 11 O’Meara JJ, McNutt RA, Evans AT. et al. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330: 1864.
• 12 The Columbus Investigators.. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
• 13 Simmoneau G, Sors H, Charbonnier B, Page Y. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.
• 14 Harenberg J, Schmitz-Huebner U. Therapie der Beinvenenthrombose mit niedermolekularen Heparinen. Deutsches Ärzteblatt 1997; 94: 2257-60.
• 15 Diuguid DL. Oral anticoagulant therapy for venous thromboembolism. N Engl J Med 1997; 336: 433-4.
• 16 Rosendaal FR. The scylla and charybdis of oral anticoagulant treatment. N Engl J Med 1996; 335: 587-9.
• 17 Raschke RA, Reilly BM, Guidry JR. et al. The weight-based heparin dosing nomogram compared with “standard care” nomogram. Ann Intern Med 1993; 119: 874-81.
• 18 Hommes DW, Bura A, Mazzolai L. et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Int Med 1992; 116: 279-84.
• 19 Bounameaux H. Medikamentöse Therapie der tiefen Venenthrombose. Ther Umschau 1996; 53: 272-6.
• 20 Partsch H. Compression therapy of legs. J Dermatol Surg Oncol 1991; 17: 799-805.
• 21 Vin F. Compression et thrombose veineuse profonde. Phlébologie 1994; 47: 35-9.
• 22 Blättler W. Ambulatory care for ambulant patients with deep vein thrombosis. J Malad Vasc 1991; 16: 137-41.
• 23 Blättler W, Borer M, Linder C, Bergan JJ. Outpatient and conventional treatment of acute deep-vein thrombosis evaluated in a controlled single-center study. Phlebologie 1988; 51: 41-6.
• 24 Levine M, Gent M, Hirsh J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
• 25 Koopman MMW, Prandoni P, Piovella F. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 677-81.
• 26 Partsch H, Oburger K, Mostbeck A, König B, Köhn H. Frequency of pulmonary embolism in ambulant patients with pelvic vein thrombosis: A prospective study. J Vasc Surg 1992; 16: 715-22.
• 27 Baldridge ED, Martin MA, Welling RE. Clinical significance of free-floating venous thrombi. J Vasc Surg 1990; 11: 62-9.
• 28 Pacouret G, Lison D, Charbonnier B, Augusseau MP, Pottier JM. Free floating thrombus and embolic risk in patients with angiographically established proximal deep venous thrombosis. A prospective study. Phlebology 1995; Suppl 1: 658-60.
• 29 Schafer AI. Low-molecular-weight heparin – an opportunity for home treatment of venous thrombosis. N Engl J Med 1996; 334: 724-5.
• 30 Blättler W, Frick E. Ambulante oder stationäre Behandlung der akuten tiefen Beinvenenthrombose: die Präferenzen der Patienten. Schweiz Med Wschr 1996; 126 (Suppl 74/I): 22S.
• 31 Mostbeck A, Partsch H, Köhn H, König B. Lungenembolie bei Bein-Beckenvenenthrombose: Ergebnisse einer prospektiven Studie. Wien Klin Wschr 1980; 92: 464-71.
• 32 Huisman MV, Büller HR, ten Cate JW. et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95: 498-502.
• 33 Decousus H, Leizorovicz A, Parent F. et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998; 338: 409-15.
• 34 Prandoni P, Lensing AWA, Büller HR, Cogo A. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33.
• 35 Nordström M, Lindblad B, Anderson H. et al. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891-4.
• 36 Netzer P, Lazarevic Hammer B. Wert des Abdomenultraschalls bei tiefer Venenthrombose. Schweiz Med Wschr 1996; 126: 58S-63S.
• 37 Research Committee of the British Thoracic Society.. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-6.
• 38 Sarasin FP, Bounameaux H. Duration of anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemost 1994; 71: 286-91.
• 39 Schulman S, Rhedin AS, Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
• 40 Schulman S, Granqvist S, Holmström M. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
• 41 Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 1995; 238: 31-7.
• 42 Weiss N. Third-generation oral contraceptives: how risky?. Lancet 1995; 346: 1570.
• 43 Devor M. et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82.